Nashik-based Datar Cancer Genetics (DCG) has launched Exacta AI, a next generation multi-analyte artificial intelligence (AI)-driven platform providing optimised treatment options for cancer patients who have exhausted the standard options.
It integrates a 360° tumour work-up and AI assisted data analysis to decode complex tumour interactome data-including molecular (NGS: DNA+RNA), proteomic, genomic, functional, and clinical insights—providing personalised treatment options with thorough risk-benefit analysis.
Exacta AI processes real-time wet lab data and integrates it with knowledge from multiple sources to assess drug synergy, interactions, toxicity, and contraindications for Anti-body Drug Conjugates (ADC)s, Checkpoint Inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapy agents and repurposed drugs.
It can recommend up to 10 evidence-based multi-drug treatment combinations for evaluation by oncologists or molecular tumour boards (MTBs), offering new hope where no standard of care exists for refractory / recurrent cancer patients.
"What makes Exacta AI truly unique is its ability to think like an entire team of multi-disciplinary experts, all at once," explains Dr Vineet Datta, Senior Director – Global Strategy and Business Development, DCG. "The platform processes information the way a molecular biologist, cancer cell expert, pharmacologist, and clinical oncologist would do, only in minutes instead of several days. By applying rational scoring steps to analyze vast datasets, Exacta AI delivers highly refined interpretations, offering an unprecedented level of precision in generating treatment options."
